High response rates and manageable safety were seen across high-risk patient groups
— High response rates and manageable safety were seen across high-risk patient groups
by Gregory Laub, Senior Director, Video, MedPage Today
July 2, 2026
• 2 min read
Real-world data presented at the American Society of Clinical Oncology (ASCO) annual meeting reinforced the effectiveness and safety of bispecific antibodies for patients with relapsed or refractory follicular lymphoma, including those with high-risk disease features.
'Some of the most effective therapies we have,' says Loretta Nastoupil
BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA…
In this video, Paolo Strati, MD, discusses the potential of bispecific antibody and antibody-drug conjugate combination therapy…
A dual-target CD19/BCMA chimeric antigen receptor T-cell therapy yielded “profound, sustained” remission in 11 patients with…
CHICAGO — The bispecific antibody linvoseltamab exhibited rapid clinical activity among patients with relapsed or refractory…
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway…
